Moderna has announced a 10% workforce reduction as part of a broader initiative to reduce operating expenses by $1.5 billion by 2027, driven by declining COVID-19 vaccine sales and increased regulatory scrutiny. CEO Stéphane Bancel emphasized the necessity of aligning costs with current business realities while maintaining scientific investment priorities. Despite short-term financial pressures, Moderna continues to pursue strategic partnerships over mergers and acquisitions to access novel technologies and advance its portfolio.